Home » Stocks » Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (REGN)

Stock Price: $598.86 USD -9.38 (-1.54%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $596.40 -2.46 (-0.41%) Aug 11, 7:59 PM

Stock Price Chart

Key Info

Market Cap 63.71B
Revenue (ttm) 8.69B
Net Income (ttm) 2.98B
Shares Out 104.54M
EPS (ttm) 25.83
PE Ratio 23.18
Forward PE 22.62
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $598.86
Previous Close $608.24
Change ($) -9.38
Change (%) -1.54%
Day's Open 601.11
Day's Range 592.45 - 608.24
Day's Volume 586,165
52-Week Range 271.37 - 664.64

More Stats

Market Cap 63.71B
Enterprise Value 62.79B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 104.54M
Float 100.48M
EPS (basic) 27.26
EPS (diluted) 25.83
FCF / Share 22.13
Dividend n/a
Dividend Yield n/a
Earnings Yield 4.31%
FCF Yield 3.81%
Payout Ratio n/a
Shares Short 2.12M
Short Ratio 1.99
Short % of Float 2.72%
Beta 0.55
PE Ratio 23.18
Forward PE 22.62
P/FCF Ratio 26.27
PS Ratio 7.33
PB Ratio 7.14
Revenue 8.69B
Operating Income 2.77B
Net Income 2.98B
Free Cash Flow 2.43B
Net Cash 928.30M
Net Cash / Share 8.73
Gross Margin 46.53%
Operating Margin 31.87%
Profit Margin 37.30%
FCF Margin 27.90%
ROA 12.71%
ROE 31.72%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (27)

Buy 14
Overweight 1
Hold 11
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$672.54*
(12.30% upside)
Low
550
Current: $598.86
High
800
Target: 672.54
*Average 12-month price target from 24 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7,8636,7115,8724,8604,1042,8202,1051,378446459
Revenue Growth17.18%14.28%20.82%18.44%45.55%33.96%52.69%209.2%-2.89%-
Gross Profit7,0816,2775,4754,5613,7112,6151,9491,294442457
Operating Income2,2102,5342,0801,3311,252824743458-205-97.47
Net Income2,1162,4441,199896636338414750-222-104
Shares Outstanding10910810610510310197.9294.6990.6182.93
Earnings Per Share18.4621.2910.347.705.522.983.726.75-2.45-1.26
EPS Growth-13.29%105.9%34.29%39.49%85.23%-19.89%-44.89%---
Operating Cash Flow2,4302,1951,3071,4861,331752589-74.62-14299.22
Capital Expenditures-430-383-273-512-678-333-156-49.34-57.22-99.69
Free Cash Flow2,0001,8121,035974653419432-124-199-0.47
Cash & Equivalents3,2142,8101,4101,0391,045900694308527249
Total Debt714709704481363458505457436160
Net Cash / Debt2,5002,101706558682443189-14991.4189.34
Assets14,80511,7358,7646,9735,6093,8382,9512,0801,3241,089
Liabilities3,7162,9772,6202,5241,9541,287999835838562
Book Value11,0908,7576,1444,4493,6552,5501,9521,245486528
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Regeneron Pharmaceuticals, Inc.
Country United States
Employees 8,142
CEO Leonard S. Schleifer

Stock Information

Ticker Symbol REGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: REGN
IPO Date April 2, 1991

Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.